Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics
Ziopharm Oncology, Inc. (NASDAQ: ZIOP) and Celldex Therapeutics, Inc. (NASDAQ: CLDX) are both clinical-stage biotechs that could make you rich, but they'll need to carry at least one of their new cancer drug candidates across the finish line first. Let's look at some of the opportunities in front of these companies, and challenges they'll face along the way, to see which one is the better stock to buy at the moment.
This stock popped in August when Gilead Sciences offered $11.9 billion to Kite Pharma, which is another clinical-stage biotech developing CAR-T therapies. Kite's lead candidate, axi-cel, is basically an infusion of a patient's own immune cells trained to hunt for cancer cells that display the CD19 protein on their surface.
Image source: Getty Images.
Source: Fool.com
Gilead Sciences Inc Aktie
Eine klare Neigung zu Buy-Einschätzungen bei Gilead Sciences Inc, ohne Sell-Einschätzungen.
Ein Kursziel von 85 € für Gilead Sciences Inc zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 71.02 €.
